GLP 1

The way Americans access GLP-1 prescriptions has shifted radically since 2021.

Wait lists for GLP-1 access were a 2022-2023 problem when Wegovy and Zepbound launched and demand outstripped supply.

Yes, Wegovy (semaglutide 2.4 mg) is FDA-approved for adolescents aged 12 and older with obesity, and Saxenda has been approved for teens since 2020.

There’s no FDA-approved taper protocol for semaglutide or tirzepatide. The label says to stop the medication, that’s it.

There’s no script for this.

There are good reasons to switch GLP-1 medications mid-treatment. Side effects on one agent that don’t show up on another. Plateaued weight loss.

When your usual GLP-1 medication is unavailable for weeks, switching to a different drug can preserve clinical progress.

Patients move between GLP-1 telehealth platforms more often than any other category, and ShedRx to TrimRx is one of the common paths.

Moving a GLP-1 prescription from one telehealth provider to another isn’t a simple transfer.